Negative Affect Task for Binge Eating Disorder
What You Need to Know Before You Apply
What is the purpose of this trial?
Binge-eating is characterized by recurrent episodes of eating large amounts of - typically high calorie - foods, eating much more rapidly than normal and until feeling uncomfortably full, as well as feeling disgusted with oneself, depressed, or guilty after those episodes. Two eating disorders are characterized by binge-eating as central diagnostic criteria, binge-eating disorder (BED) and bulimia nervosa (BN). Binge-eating episodes in BN, but not BED, are typically followed by compensatory mechanisms such as self-induced vomiting, and BED is typically associated with obesity, while BN is not. Behavior studies such as ecological momentary assessment (EMA) research of affect in an individual's naturalistic environment have shown that negative affect and negative urgency (the tendency to act rashly when distressed) often precede binge-eating.The Investigators want to answer the following questions: Can negative affect in BN and BED be linked to 1) altered dopamine related brain reinforcement learning, 2) to food value computation and cognitive control circuit function, and 3) can dopamine related brain activation predict eating and negative affect, indicating a brain based neurobiological vulnerability. Answering those questions will help to define binge-eating based on regulation of brain reward, cognition, and emotion circuit function and point toward potential psychopharmacological interventions to normalize brain function and behavior.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does exclude participants who are on medications other than birth control pills (BCP) or intrauterine devices (IUD) for healthy controls and obese participants. For those with Binge Eating Disorder or Bulimia Nervosa, there is no mention of stopping current medications, but certain medications like psychostimulants are excluded.
How does the Negative Affect Task treatment differ from other treatments for binge eating disorder?
The Negative Affect Task treatment is unique because it focuses on understanding and modifying the emotional responses (negative feelings) that often precede binge eating episodes, rather than directly targeting eating behaviors. This approach is based on the idea that changes in emotions can influence binge eating, which is different from traditional treatments that may focus more on dietary changes or cognitive-behavioral strategies.12345
What data supports the effectiveness of the treatment Negative Affect Task for Binge Eating Disorder?
Research suggests that changes in negative emotions (like stress or guilt) are linked to binge eating, and managing these emotions can help reduce binge episodes. The Negative Affect Task may help by addressing these emotional changes, as studies show that improvements in negative emotions can decrease binge eating behavior.12345
Who Is on the Research Team?
Guido KW Frank, MD
Principal Investigator
University of California, San Diego
Are You a Good Fit for This Trial?
Adults aged 18-55 with obesity (BMI > 30 kg/m2) and diagnosed with Bulimia Nervosa or Binge Eating Disorder, experiencing marked distress from binge eating. Participants should have a stable weight and food intake for the past month, no major medical illnesses, no history of substance abuse or certain psychiatric disorders, not pregnant or breastfeeding, and without metal implants.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Experimental Task Phase
Participants undergo fMRI tasks to study brain activation in response to negative affect during taste reward and food choice paradigms
Follow-up
Participants are monitored for brain activation and food intake/negative affect relationships over a long-term period
What Are the Treatments Tested in This Trial?
Interventions
- Negative Affect Task
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor
Sanford Research
Collaborator
University of Colorado, Denver
Collaborator